EMA additional information demand puts increased pressure on pharma businesses
The European Medicines Agency (EMA) has asked pharma businesses to update and improve the quality of information on all products which are submitted to the EMA by the end of December. The additional...
View ArticleThe Medical Research Council to release £7m of funding to AstraZeneca...
The Medical Research Council (“MRC”) has announced that it will be committing £7 million of funding to 15 academic drug research projects. The 15 projects were selected by the MRC on the basis of...
View ArticleLord Howe praises community pharmacy at the Pharmacy Business Awards 2012
At this year’s Pharmacy Business Awards, chief guest Lord Howe proclaimed his admiration for community pharmacists across the nation for being supreme healthcare clinicians, declaring that “[t]o the...
View ArticleUK Government awards £1 billion in funding to Science and Research Projects
The UK Government has injected a further £1 billion of funding for seven new projects in science and research. This newest round of projects takes The UK Research Partnership Investment Fund’s (“RPIF”)...
View ArticleSupplemental Protection Certificates and the “First Authorisation” Rule
AstraZeneca AB v Comptroller-General of Patents, Designs and Trade Marks, High Court; Case numbers CH/2012/0232 and CH/2012/0489 The High Court has once again decided to refer questions of...
View ArticleAstraZeneca secures strategic partnership with Charles River Laboratories
Charles River Laboratories International Inc. (“Charles River”) has today announced that it has been selected by AstraZeneca as AstraZeneca’s preferred strategic partner in a three year agreement to...
View ArticleBen Goldacre challenges ABPI’s statement on his book, “Bad Pharma”
Ben Goldacre has stated in his “bad science” blog on 11 October 2012 that, “The ABPI claims that all the problems in my book are “historical”. This claim is simply untrue.” Ben Goldacre goes on to set...
View ArticleSupplementary Protection Certificates – High Court refers questions to be...
Actavis v Sanofi, High Court To the frustration of the parties and judge alike, the High Court has decided to refer particular questions on the interpretation of Article 3(a),(c) and (d) of the...
View ArticleABPI release statement on Ben Goldacre’s “Bad Pharma”
The Association of the British Pharmaceutical Industry (“ABPI”), the body that represents the big pharma suppliers, has released its reaction to the controversial new book, “Bad Pharma” by Ben...
View ArticleA small step for Cipla, a giant step for Generic Kind
The Indian generics company, Cipla, has grabbed the headlines not once but twice over the last few weeks for pushing the generic cause onwards and leaving big pharma feeling the effects in its wake....
View ArticleInterpol seizes over US$10 million of counterfeit and illicit drugs in...
In its mission to combat the sale of illegal medicines, Operation Pangea was launched by Interpol and its partners, consisting of customers, health regulators, national police forces and the public...
View Article90% of pharmacists see loss-leaders as dangerous
90% of pharmacists who responded to a survey by the magazine Chemist + Druggist have said that they see loss leaders by pharmacists as dangerous for independent pharmacists. Only 10% thought loss...
View ArticleInnovation crisis – what crisis?
For years, Big Pharma has been saying that they have been suffering from an innovation crisis. The reality is that the number of new drugs licensed each year has remained at between 15 and 25 over the...
View ArticleBAPW promises to do “everything” to ensure drugs get to patients during Olympics
The British Association of Pharmaceutical Wholesalers has promised that its members will do “everything” they can to ensure drugs reach patients quickly during the Olympic and Paralympic period. This...
View ArticleBig Pharma Join Resources for TB Drug Discovery
Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck and Sanofi have joined a unique partnership with several research institutions and the Bill & Melinda Gates Foundation in which they...
View ArticleAdvocate General likes the medicine handed out to AstraZeneca by lower court...
Advocate General Mazak has recommended that the European Court of Justice follows the European Union’s lower court, the General Court, in approving the European Commission’s decision and giving a €53m...
View ArticleRoyal Pharmaceutical Society calls for change in EU law to prohibit export of...
The chair of the Royal Pharmaceutical Society, Lindsey Gilpin, has called for a change to the European Union laws that permit parallel exporting of products – ie the purchase of drugs from one cheaper...
View ArticleNICE to be stripped of role of directing NHS on cost-effectiveness of drugs
The National Institute for Health and Clinical Excellence (NICE) will lose its current role of directing the National Health Service on the cost-effectiveness of drugs. Its role will be replaced by the...
View ArticleBristol Myers Squibb loses one third of its revenue overnight as Plavix the...
Bristol Myers Squibb has lost one third of its revenues overnight, as its anti-platelet therapy, Plavix, has become the latest blockbuster drug of the big pharma companies to see its patent expire....
View ArticleAbiraterone drug approval granted by NICE – but at what price?
Abiraterone, the new drug that extends the lives of people with advanced prostate cancer by three months, has been approved by the National Institute for Health and Clinical Excellence (NICE). This...
View Article
![ONEW – KAKERA -Unmei no Piece- – EP [iTunes Plus M4A]](http://is1-ssl.mzstatic.com/image/thumb/Music221/v4/d0/fb/86/d0fb86a5-ba60-4bea-41fb-7f54c125f518/VEATP-45908.jpg/296x296bb.webp)
/pic9814888.png)
